

# Theresa Bucsics

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9048881/publications.pdf>

Version: 2024-02-01

59  
papers

2,568  
citations

304743

22  
h-index

189892

50  
g-index

60  
all docs

60  
docs citations

60  
times ranked

2948  
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of Various Microplastics in Human Stool. <i>Annals of Internal Medicine</i> , 2019, 171, 453-457.	3.9	939
2	Nonselective $\beta_2$ Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis. <i>Gastroenterology</i> , 2014, 146, 1680-1690.e1.	1.3	336
3	Austrian consensus guidelines on the management and treatment of portal hypertension (Bilroth III). <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 135-158.	1.9	111
4	Interferon-free regimens improve portal hypertension and histological necroinflammation in <scp>HIV</scp>/<scp>HCV</scp> patients with advanced liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 139-149.	3.7	83
5	Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. <i>Liver International</i> , 2015, 35, 2121-2128.	3.9	72
6	Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. <i>Gastroenterology Report</i> , 2017, 5, 127-137.	1.3	68
7	Elastography-based screening for esophageal varices in patients with advanced chronic liver disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 308-329.	3.3	55
8	Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites. <i>PLoS ONE</i> , 2014, 9, e110503.	2.5	55
9	Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. <i>Gut</i> , 2021, 70, 1758-1767.	12.1	51
10	Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 194-204.	3.9	45
11	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , 2021, 73, 1275-1289.	7.3	45
12	Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 966-979.	3.7	41
13	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 446-455.	1.9	41
14	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. <i>Liver International</i> , 2019, 39, 127-135.	3.9	39
15	Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1657-1665.	2.8	37
16	Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis. <i>United European Gastroenterology Journal</i> , 2020, 8, 321-331.	3.8	30
17	Adherence to quality criteria improves concordance between transient elastography and ElastPQ for liver stiffness assessment – A multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2018, 50, 1056-1061.	0.9	29
18	Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. <i>Digestive and Liver Disease</i> , 2017, 49, 1360-1367.	0.9	28

#	ARTICLE	IF	CITATIONS
19	ePTFEâ€”TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. <i>Liver International</i> , 2018, 38, 1036-1044.	3.9	28
20	Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. <i>Liver International</i> , 2021, 41, 799-809.	3.9	27
21	Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e251-e266.	4.4	25
22	The impact of thyroid hormones on patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0181878.	2.5	24
23	The role of TIPS in the management of liver transplant candidates. <i>United European Gastroenterology Journal</i> , 2017, 5, 1100-1107.	3.8	23
24	Liver disease in adults with $\alpha$ 1-antitrypsin deficiency. <i>United European Gastroenterology Journal</i> , 2018, 6, 710-718.	3.8	23
25	The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. <i>PLoS ONE</i> , 2015, 10, e0143429.	2.5	23
26	High efficacy of interferonâ€”free therapy for acute hepatitis C in HIVâ€”positive patients. <i>United European Gastroenterology Journal</i> , 2019, 7, 507-516.	3.8	22
27	Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acuteâ€”onâ€”chronic liver failure. <i>United European Gastroenterology Journal</i> , 2021, 9, 427-437.	3.8	22
28	Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding â€” A two decades experience. <i>PLoS ONE</i> , 2018, 13, e0189414.	2.5	20
29	Impact of <i>HSD17B13</i> rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Liver International</i> , 2020, 40, 393-404.	3.9	20
30	Small Esophageal Varices in Patients with Cirrhosisâ€”Should We Treat Them?. <i>Current Hepatology Reports</i> , 2018, 17, 301-315.	0.9	17
31	Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfecting patients. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 105-114.	1.9	14
32	Nonâ€”invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1713-1724.	3.9	14
33	Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP). <i>Journal of Hepatology</i> , 2016, 64, 1452-1454.	3.7	13
34	Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-8.	1.5	13
35	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. <i>Hepatology International</i> , 2020, 14, 1093-1103.	4.2	12
36	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. <i>Hepatology International</i> , 2021, 15, 1160-1173.	4.2	12

#	ARTICLE	IF	CITATIONS
37	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2578-2586.	1.5	11
38	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. <i>Digestive and Liver Disease</i> , 2022, 54, 500-508.	0.9	11
39	The trigger matters – outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. <i>Liver International</i> , 2016, 36, 1649-1656.	3.9	10
40	The impact of hepatic steatosis on portal hypertension. <i>PLoS ONE</i> , 2019, 14, e0224506.	2.5	10
41	Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. <i>AIDS Patient Care and STDs</i> , 2019, 33, 197-206.	2.5	10
42	Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 517-526.	1.9	9
43	Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2164-2172.	2.8	9
44	Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3642-3651.	2.3	8
45	Point Shear Wave Elastography by ElastPQ for Fibrosis Screening in Patients with NAFLD: A Prospective, Multicenter Comparison to Vibration-Controlled Elastography. <i>Ultraschall in Der Medizin</i> , 2023, 44, 169-178.	1.5	8
46	Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. <i>United European Gastroenterology Journal</i> , 2019, 7, 651-661.	3.8	7
47	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. <i>Thrombosis and Haemostasis</i> , 2022, 122, 353-362.	3.4	7
48	Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5693-5703.	2.3	5
49	Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 421-431.	1.9	4
50	Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS. <i>Hepatology Communications</i> , 2022, 6, 621-632.	4.3	2
51	Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2021, 53, 345-352.	0.9	0
52	Controlled attenuation parameter (CAP®) does not predict hepatic decompensation in patients with compensated advanced chronic liver disease. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, .	0.5	0
53	The impact of hepatic steatosis on portal hypertension. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, .	0.5	0
54	The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites. , 2018, 56, .		0

#	ARTICLE	IF	CITATIONS
55	Impact of farnesoid X receptor (FXR) polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. , 2019, 57, .		0
56	Reliability criteria for controlled attenuation parameter (CAP) for assessing hepatic steatosis using transient elastography. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
57	Transjugular intrahepatic portosystemic shunt implantation improves renal function in patients with ascites. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
58	Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
59	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. , 2021, 59, .		0